Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SJP1602
- Development stage
- Preclinical
- Lead developer
- Samjin Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SJP1602 is an orally bioavailable small molecule dual inhibitor of focal adhesion kinase (FAK) and protein tyrosine kinase 2 beta (PYK2), currently in preclinical development by Samjin Pharmaceutical in collaboration with Incheon National University. SJP1602 is designed to target the growth, migration, invasion, and metastatic progression of cancer cells, with a primary focus on triple-negative breast cancer (TNBC) and other solid tumors. Preclinical studies have demonstrated that SJP1602 effectively inhibits both FAK and PYK2, showing superior efficacy in suppressing tumor growth and cancer stem cell activity compared to single-target FAK inhibitors.
02
Targets
FAK (Focal adhesion kinase)PTK2B
Beyond the preview
Go deeper on SJP1602.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SJP1602.